TransMedics Group Analyst Price Targets

Wall Street analyst price targets and consensus rating for TransMedics Group (TMDX).

Price Target Range — 13 Quarters

Analyst Consensus — 13 Analysts

10Buy

3Hold

Consensus RatingBuy# Analysts13Avg. Consensus PT$114Upside to Avg. PT+43.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 7, 2026	Barclays	Christopher Pasquale	Initiate	Overweight	$120
Sep 8, 2026	TD Cowen	Joshua Jennings	Maintained	Buy	$120
Aug 5, 2026	UBS	Patrick Wood	PT Cut	Neutral	$80→$77
Aug 5, 2026	Piper Sandler	Matt O'Brien	PT Cut	Overweight	$120→$100
Aug 3, 2026	Needham	Mike Matson	PT Cut	Buy	$142→$106
Jul 28, 2026	UBS	—	Initiate	Neutral	$80
Jul 6, 2026	Evercore ISI Group	Daniel Markowitz	PT Cut	Outperform	$100→$90
Jul 1, 2026	TD Cowen	Joshua Jennings	Maintained	Buy	$120
Jun 30, 2026	Canaccord Genuity	William Plovanic	Maintained	Buy	$124
Jun 18, 2026	Stifel	Tom Stephan	PT Raise	Hold	$75→$80
May 26, 2026	Stifel	Tom Stephan	PT Cut	Hold	$85→$75
May 6, 2026	Canaccord Genuity	William Plovanic	PT Cut	Buy	$152→$124
May 6, 2026	TD Cowen	Joshua Jennings	PT Cut	Buy	$190→$120
May 6, 2026	Stifel	Thomas Stephan	PT Cut	Hold	$130→$85
May 6, 2026	Piper Sandler	Matt O'Brien	PT Cut	Overweight	$160→$120
May 6, 2026	Needham	Mike Matson	PT Cut	Buy	$174→$142
Apr 6, 2026	Evercore ISI Group	Daniel Markowitz	PT Cut	Outperform	$170→$118
Mar 9, 2026	Stifel	Thomas Stephan	PT Raise	Hold	$115→$130
Feb 25, 2026	JP Morgan	Allen Gong	PT Raise	Neutral	$114→$149
Feb 25, 2026	Oppenheimer	Suraj Kalia	PT Raise	Outperform	$150→$175

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Initiates Coverage On TransMedics Group with Overweight Rating, Announces Price Target of $120

Barclays analyst Christopher Pasquale initiates coverage on TransMedics Group (NASDAQ:TMDX) with a Overweight rating and announces Price Target of $120.

Benzinga Newsdesk

PRO
TD Cowen Reiterates Buy on TransMedics Group, Maintains $120 Price Target

TD Cowen analyst Joshua Jennings reiterates TransMedics Group (NASDAQ:TMDX) with a Buy and maintains $120 price target.

Benzinga Newsdesk

PRO
UBS Maintains Neutral on TransMedics Group, Lowers Price Target to $77

UBS analyst Patrick Wood maintains TransMedics Group (NASDAQ:TMDX) with a Neutral and lowers the price target from $80 to $77.

Benzinga Newsdesk

PRO
Piper Sandler Reiterates Overweight on TransMedics Group, Lowers Price Target to $100

Piper Sandler analyst Matt O'Brien reiterates TransMedics Group (NASDAQ:TMDX) with a Overweight and lowers the price target from $120 to $100.

Benzinga Newsdesk

PRO
Needham Maintains Buy on TransMedics Group, Lowers Price Target to $106

Needham analyst Mike Matson maintains TransMedics Group (NASDAQ:TMDX) with a Buy and lowers the price target from $142 to $106.

Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on TransMedics Group, Lowers Price Target to $90

Evercore ISI Group analyst Daniel Markowitz maintains TransMedics Group (NASDAQ:TMDX) with a Outperform and lowers the price target from $100 to $90.

Benzinga Newsdesk

TransMedics Group Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

TransMedics Group Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Barclays Initiates Coverage On TransMedics Group with Overweight Rating, Announces Price Target of $120

PRO
TD Cowen Reiterates Buy on TransMedics Group, Maintains $120 Price Target

PRO
UBS Maintains Neutral on TransMedics Group, Lowers Price Target to $77

PRO
Piper Sandler Reiterates Overweight on TransMedics Group, Lowers Price Target to $100

PRO
Needham Maintains Buy on TransMedics Group, Lowers Price Target to $106

PRO
Evercore ISI Group Maintains Outperform on TransMedics Group, Lowers Price Target to $90

People Also Watch

People Also Watch

TransMedics Group Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

TransMedics Group Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBarclays Initiates Coverage On TransMedics Group with Overweight Rating, Announces Price Target of $120

PROTD Cowen Reiterates Buy on TransMedics Group, Maintains $120 Price Target

PROUBS Maintains Neutral on TransMedics Group, Lowers Price Target to $77

PROPiper Sandler Reiterates Overweight on TransMedics Group, Lowers Price Target to $100

PRONeedham Maintains Buy on TransMedics Group, Lowers Price Target to $106

PROEvercore ISI Group Maintains Outperform on TransMedics Group, Lowers Price Target to $90

People Also Watch

People Also Watch

PRO
Barclays Initiates Coverage On TransMedics Group with Overweight Rating, Announces Price Target of $120

PRO
TD Cowen Reiterates Buy on TransMedics Group, Maintains $120 Price Target

PRO
UBS Maintains Neutral on TransMedics Group, Lowers Price Target to $77

PRO
Piper Sandler Reiterates Overweight on TransMedics Group, Lowers Price Target to $100

PRO
Needham Maintains Buy on TransMedics Group, Lowers Price Target to $106

PRO
Evercore ISI Group Maintains Outperform on TransMedics Group, Lowers Price Target to $90